Filing Flows › Rhythm Pharmaceuticals (RYTM) › Q3 2025
Rhythm Pharmaceuticals (RYTM) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 4, 2025
Rhythm Pharmaceuticals (RYTM) reported revenue of $51.3M for the third quarter 2025 (Q3 2025), +54% from a year earlier and +6% from the quarter before. Operating margin was -102.6%, net loss $52.9M (103.1% of revenue).
Rhythm Pharmaceuticals, Q3 2025: revenue $51.3M (+54% year over year), operating margin -102.6%, net loss $52.9M, operating cash flow −$26.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $51.3M | +6% | +54% |
| Operating profit | −$52.7M | — | — |
| Net earnings | −$52.9M | — | — |
| Operating cash flow | −$26.6M | — | — |
What changed
Revenue was $51.3M in Q3 2025, up 54% year over year and up 6% from the previous quarter.
Operating costs exceeded revenue by $52.7M, an operating margin of -102.6%. Total costs grew 35% against revenue growth of 54%. The fastest-growing cost line was SG&A (+48%). The quarter ended with a net loss of $52.9M, wider than the previous quarter's $46.6M loss.
Operating cash flow was −$26.6M. Non-cash charges added back $18.8M of share-based compensation. Working capital and other items added $7.5M.
Questions
What was Rhythm Pharmaceuticals' revenue in the third quarter 2025?
Rhythm Pharmaceuticals (RYTM) reported revenue of $51.3M for the third quarter 2025 (Q3 2025), +54% from a year earlier and +6% from the quarter before.
Was Rhythm Pharmaceuticals profitable in the third quarter 2025?
Operating loss was $52.7M (-102.6% of revenue) and net loss $52.9M.